Tango Therapeutics, Inc.
TNGX
주식 순위
#4544
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
주가
$27.18
마지막 동기화: 2026-07-31
시가총액
$3.38B
변동 (1일)
-1.41%
변동 (1년)
202.34%
국가
US
거래 Tango Therapeutics, Inc. (TNGX)
카테고리
Healthcare
Tango Therapeutics, Inc. (TNGX)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 67.14
Tango Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 67.14입니다. 2023년 말 기준 P/S 비율은 25.63였습니다.
Tango Therapeutics, Inc.의 P/S 비율 기록 (2019 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 67.14 | 737.15% |
| 2024 | 8.02 | -68.70% |
| 2023 | 25.63 | 0.08% |
| 2022 | 25.61 | 39.62% |
| 2021 | 18.34 | -61.56% |
| 2020 | 47.71 | 1,179.46% |
| 2019 | 3.73 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 10.02 | -85.07% |
US
|
|
| 40.55 | -39.60% |
US
|
|
| 3.96 | -94.10% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -84.89% |
NL
|
